Antibiotic treatment strategies for Helicobacter pylori infection

Sma Campo, A Zullo, Cesare Hassan, S. Morini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

22 Citazioni (Scopus)


In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.
Lingua originaleEnglish
pagine (da-a)11-17
Numero di pagine7
RivistaRecent Patents on Anti-Infective Drug Discovery
Stato di pubblicazionePubblicato - 2007
Pubblicato esternamente


  • Animals
  • Anti-Bacterial Agents
  • Helicobacter Infections
  • Helicobacter pylori
  • Humans
  • Microbial Sensitivity Tests
  • Patents as Topic
  • Stomach Ulcer


Entra nei temi di ricerca di 'Antibiotic treatment strategies for Helicobacter pylori infection'. Insieme formano una fingerprint unica.

Cita questo